U.S. FDA approves Kaléo’s Auvi-Q (epinephrine injection, USP) 0.1 mg auto-injector for life-threatening allergic reactions in infants and small children The U.S. Food and Drug Administration (FDA) has approved Kaléo’s supplemental New Drug Application (sNDA) for Auvi-Q (epinephrine injection, USP) 0.1 mg, the first and only epinephrine auto-injector (EAI) specifically designed for the treatment of life-threatening…